[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhejiang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":681},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,128,0,25,[9,44,73,102,125,154,184,208,239,266,294,319,345,367,396,422,443,470,494,519,548,577,601,623,653],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642345","efficacy-and-safety-of-the-visual-bronchial-blocker-for-lung-isolation-surgery-100642345",false,"NCT07644104","Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery","Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* ASA physical status I-III\n* Scheduled for elective thoracic surgery (pulmonary, esophageal, or mediastinal procedures) requiring one-lung ventilation and lung isolation\n* Able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n* Anatomical abnormalities of the tracheobronchial tree, including anomalous right upper lobe bronchial origin, severe airway stenosis, or distortion\n* Planned bronchial sleeve resection or carinal surgery\n* Empyema, bronchopleural fistula, or severe pleural adhesions affecting bronchial anatomy\n* Previous thoracic surgery that altered bronchial anatomy\n* Severe cardiopulmonary dysfunction with a metabolic equivalent (MET) \\\u003C 4\n* Severe psychiatric disorders or inability to cooperate with anesthesia procedures\n* Current participation in another interventional clinical trial\n* Contraindications to bronchial blocker placement (e.g., known allergy to materials used, high risk of airway trauma)","ALL","18 Years",{"count":20,"type":21},652,"ESTIMATED","INTERVENTIONAL",[24],"NA","This multicenter, prospective, randomized, controlled clinical trial is initiated by the First Affiliated Hospital of Zhejiang University School of Medicine, with participation from Peking Union Medical College Hospital, the Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, and Shanxi Bethune Hospital. The study aims to compare the first-attempt placement success rate between visual bronchial blockers (VBB, test group) and conventional bronchial blockers (CBB, control group) during anesthesia for thoracic surgery, and to evaluate operational efficiency, lung isolation quality, and safety profiles.\n\nA total of 652 patients aged ≥18 years with ASA physical status I-III, scheduled for elective pulmonary, esophageal, or mediastinal surgery requiring lung isolation, will be enrolled in a 1:1 ratio (326 per group), with a 10% anticipated dropout rate. Key exclusion criteria include anomalous right upper lobe bronchial origin, severe airway anatomical abnormalities, bronchial sleeve resection, empyema, bronchopleural fistula, previous thoracic surgery altering bronchial anatomy, severe cardiopulmonary dysfunction (metabolic equivalent \\\u003C4), severe psychiatric disorders, and concurrent participation in other clinical trials.\n\nFollowing standardized anesthesia induction with rocuronium (2-3 × ED95), patients undergo tracheal intubation using a video laryngoscope. In the CBB group, placement is guided by blind probing and auscultation, with confirmation via fiberoptic bronchoscopy (FOB). In the VBB group, placement is performed under direct vision using the integrated camera, with FOB rescue allowed only if visualization fails (rescue cases are counted as failures). Placement success is defined as the cuff located in the ipsilateral main bronchus with the proximal cuff edge immediately below the carina.\n\nPrimary endpoint: First-attempt placement success rate. Secondary endpoints: Time to successful first placement, lung collapse grade (Likert 3-point scale), cumulative number and duration of FOB use, intraoperative blocker displacement, hypoxemia (SpO₂ \\\u003C90% or \\\u003C85% for ≥5 seconds), airway injury, hemodynamic changes, postoperative sore throat, hoarseness, hospital length of stay, ICU admission rate, postoperative pulmonary complications, and 30-day all-cause mortality. Operator and surgeon satisfaction will be rated on a 0-10 scale.\n\nRandomization is centralized, stratified by center, using variable block sizes (4, 6, or 8) to ensure allocation concealment. Outcome assessors and patients are blinded to group assignment, while operators are not. An independent Endpoint Adjudication Committee will review imaging data for blinded verification.\n\nStatistical analysis will be performed using SPSS 27.0 and R software. Baseline characteristics will be compared using independent samples t-test, Mann-Whitney U test, chi-square test, or Fisher's exact test as appropriate. The primary endpoint (binary variable) will be analyzed using generalized linear mixed models (GLMM) with center as a random effect and logistic regression as a sensitivity analysis. A two-sided P\\\u003C0.05 is considered statistically significant. Full Analysis Set (intention-to-treat), Per-Protocol Set, and Safety Set will be defined for efficacy and safety evaluations.\n\nThe trial timeline includes registration and training (June 2026 - August 2026), patient recruitment and data collection (September 2026 - September 2027), and data analysis, manuscript preparation, and publication (October 2027 - Dec 2028). Adverse events will be monitored, documented, and reported in accordance with CTCAE v5.0; serious adverse events will be reported to the ethics committee within 24 hours.\n\nThis study is the first randomized controlled trial evaluating a visual bronchial blocker worldwide. The investigators hypothesize that VBB improves first-attempt placement success, shortens positioning time, reduces FOB reliance, enhances lung collapse quality, decreases intraoperative displacement and hypoxemia, and lowers airway injury and postoperative complications. The results will provide high-level evidence for the clinical application of VBB in thoracic anesthesia and promote the visualization and standardization of one-lung ventilation techniques.",[27,28,29,30],"Thoracic Surgery With One-lung Ventilation","Lung Isolation","Bronchial Blockage","Anesthesia","NOT_YET_RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":21},"2026-08-01",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Zhejiang University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":71,"locationsCount":72},"100642549","supraglottic-oxygenation-via-oral-transtracheal-catheter-for-reducing-the-incidence-of-hypoxemia-during-ercp-under-sedation-100642549","NCT07637721","Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation","Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation：a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age≥18years\n* The ASA classification ranges from I to III\n* Patients have signed the informed consent form\n* Patients scheduled to undergo sedated ERCP examination procedure\n\nExclusion Criteria:\n\n* Severe cardiac dysfunction (\\\u003C4 METs);\n* Diagnosed chronic obstructive pulmonary disease (COPD) or other acute\u002Fchronic pulmonary diseases requiring long-term\u002Fintermittent oxygen therapy;\n* Upper respiratory tract infections including oral, nasal or pharyngeal infections;\n* Fever (core temperature \\>37.5°C);\n* Confirmed pregnancy or current breastfeeding;\n* Hypersensitivity to sedative drugs such as propofol;\n* Current participation in other clinical trials;",{"count":52,"type":21},410,[24],"Endoscopic retrograde cholangiopancreatography (ERCP) is commonly used for the diagnosis and treatment of pancreatobiliary diseases. While Monitored Anesthesia Care (MAC) enhances the efficiency of ERCP, deep sedation introduces significant airway risks, particularly hypoxemia resulting from sedative-induced upper airway collapse. With reported hypoxemia rates ranging from 10% to 69%, and the potential for severe complications such as myocardial ischemia and neurological damage, effective airway management is paramount. Supraglottic oxygenation via oral transtracheal catheter provides a viable method for relieving obstruction and enabling positive pressure ventilation, serving as a less invasive alternative to tracheal intubation. Despite its proven utility in other settings, this technique has not yet been evaluated in the context of deeply sedated ERCP.",[56,57,58,59],"Choledocholithiasis With Cholecystitis With Obstruction","Obstructive Jaundice","Pancreatitis","Cholelithiasis",[61,62,63,64,65],"ERCP","Monitored Anesthesia Care","deep sedation","hypoxemia","The Supraglottic Oxygenation Via Oral Transtracheal Catheter","2026-06-09",{"date":68,"type":35},"2026-06-10",{"date":34,"type":21},{"date":39,"type":21},{"name":41,"class":42},3,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":43},"100484853","phase-3-transarterial-neoadjuvant-chemotherapy-vstraditional-intravenous-chemotherapy-for-locally-advanced-gastric-cancer-with-soxpd-1-100484853","NCT05593458","Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1","A Multicenter, Randomized, Controlled Study of S-1 Combined With Oxaliplatin by Arterial Infusion Plus PD-1 Antibody Versus Conventional SOX Chemotherapy Plus PD-1 Antibody for Locally Advanced Gastric Cancer","TACTIC","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group(ECOG) score 0-1\n* Ambulatory males or females, aged 18-75 years\n* Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II or III)\n* Locally advanced gastric carcinoma (cT3N2-3M0, cT4aN1-3M0, cT4bNanyM0, American Joint Committee on Cancer (AJCC) TNM staging system 8th edition)\n* Life expectancy more than 3 months\n* Give written informed consent, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.\n* Normal hepatic, renal, and bone marrow function (ALT\u002FAST\\\u003C2.5 fold of upper limit value;Tbil\\\u003C1.5mg\u002Fdl, Cr\\\u003C1.5 fold of upper limit value; White Blood Cell count≥3 × 10\\^9\u002FL, ANC ≥ 1.5 × 10\\^9\u002FL,PLT≥ 80 × 10\\^9\u002FL,Hb ≥ 90 g\u002FL).\n\nExclusion Criteria:\n\n* Patients can not bear surgical procedure.\n* Pregnant or lactating women.\n* HER2 overexpression(+++) confirmed by immunohistochemistry.\n* Previous cytotoxic chemotherapy, radiotherapy or immunotherapy.\n* History of another malignancy within the last five years.\n* History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the Investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.\n* Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months.\n* History of dysphagia, complete or partial gastrointestinal obstruction, active gastrointestinal bleeding and gastrointestinal perforation;\n* Organ allografts requiring immunosuppressive therapy.\n* Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.\n* Moderate or severe renal impairment: serum creatinine \\> 1.5 x upper limit of normal (ULN).\n* Hypersensitivity to any drug of the study regimen.\n* With abdominal cavity implantation metastasis or distant metastasis.\n* Unwilling or unable to comply with the protocol for the duration of the study.","75 Years",{"count":83,"type":21},190,[85],"PHASE3","SOX regimen, consisting of oral S-1 and intravenous oxaliplatin, is the preferred regimen for perioperative chemotherapy for gastric cancer. The goal of this clinical trial is to compare the efficacy and safety between S-1 combined with oxaliplatin by arterial infusion, as neoadjuvant chemotherapy, and conventional SOX regimen, in locally advanced gastric cancer. The main question it aims to answer is: whether arterially infused oxaliplatin plus S-1 has the potential to be a better neoadjuvant option for patients with locally advanced gastric cancer.\n\nParticipants will be randomised, and receive:\n\n* 3 cycles of conventional SOX chemotherapy plus PD-1 antibody or arterial infused oxaliplatin plus S-1 and PD-1 antibody, as neoadjuvant chemotherapy;\n* Adequate gastric resection along with D2 lymph node dissection;\n* 3 cycles adjuvant chemotherapy using SOX regimen plus PD-1 antibody.\n* Administration of S-1 regularly till 1 year after surgery.\n\nResearchers will compare Major pathological response rate (MPR) ，pathologic complete response rate（pCR）,the 2-year overall survival (OS) rates, 2-year disease free survival (DFS), R0 resection rates, and adverse events, to see if the modified perioperative chemotherapy improve the prognosis of patients with locally advanced gastric cancer.",[88],"Locally Advanced Gastric Carcinoma",[90,91,92,93],"gastric cancer","arterial infusion","neoadjuvant therapy","immunotherapy","RECRUITING","2026-06-08",{"date":32,"type":35},{"date":98,"type":35},"2023-03-01",{"date":100,"type":21},"2026-12",{"name":41,"class":42},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100575297","phase-2-hrs-4642-with-nimotuzumab-and-chemotherapy-for-first-line-treatment-of-advanced-pancreatic-cancer-patients-100575297","NCT06770452","HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","A Single-arm Phase II Study of HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients With KRAS G12D Mutations","Inclusion Criteria:\n\n1.Age: 18-75 (including 18 and 75); 2.Metastatic pancreatic cancer (from pancreatic ductal epithelium) for Arm A; Locally advanced pancreatic cancer (from pancreatic ductal epithelium) for Arm B; 3.Tumor tissue contains KRAS G12D mutation; 4.No systemic antitumor therapy in advanced stage; if previous neoadjuvant \u002F adjuvant therapy, last treatment should be over 6 months; 5.At least one measurable lesion according to the RECIST v1.1 criteria; 6.The ECOG (Eastern Cooperative Oncology) score was 0-1; 7.Expected survival period of 3 months; 8.The functions of vital organs meets the following requirements (any blood components, cell growth factors are not allowed 2 weeks prior to enrollment):\n\n1. Neutrophil count≥1.5×10\\^9 \u002F L;\n2. Platelet≥100×10\\^9 \u002F L;\n3. Hemoglobin≥100 g \u002F L;\n4. Serum albumin≥30 g \u002F L;\n5. Total bilirubin≤1.5×ULN; ALT, AST≤3×ULN and ALP≤2.5×ULN; if the patient has liver metastasis, ALT, ALT and AST≤5×ULN; if the patient has liver or bone metastasis, ALP≤5×ULN;\n6. Creatinine clearance≥50 mL\u002Fmin or serum creatinine ≤1.5×ULN;\n7. Urinary protein \\\u003C2+; if urine protein≥2+, an additional 24 hours urine protein quantification should be tested, and if 24 hours urine protein quantification \\\u003C1g can be enrolled;\n8. ECG: QTcF≤450 ms (male), QTcF≤470 ms (female);\n9. Cardiac color ultrasound: LVEF (left ventricular ejection fraction) ≥50%; 9.Women of childbearing age must have a blood pregnancy test within 7 days before enrollment, the result should be negative and must be non-lactating and should be willing to use appropriate contraception during the trial and within 6 months of treatment. For men, surgical sterilization or consent to use appropriate contraception during the study and within 6 months after completion of treatment.\n\n10.Volunteer to participate in the study and sign the informed consent form, good compliance, agreed to cooperate with the follow-up.\n\nExclusion Criteria:\n\n1.Previous treatment:\n\n1. Previous treatment of targeted therapy against KRAS G12D.\n2. Previous targeted therapy against EGFR.\n3. Received major surgery or major trauma within 4 weeks before enrollment, or palliative local treatment (including but not limited to palliative radiotherapy, interventional therapy) within 2 weeks prior to enrollment.\n4. Have received any other clinical study medication within 4 weeks before enrollment, except for an observational (non-interventional) clinical study or interventional clinical study follow-up.\n\n(5)14 days before enrollment with drugs that strongly inhibit or induce the hepatic drug-metabolizing enzymes CYP3A4 or CYP2C8.\n\n2.The presence of a central nervous system (CNS) metastases. 3.Acute or chronic pancreatitis requiring clinical intervention. 4.Symptoms and signs of gastrointestinal obstruction or obstruction within 6 months before initiation of study treatment but can be screened if surgery is performed and the obstruction is completely resolved.\n\n5.Within 2 weeks prior to enrollment, there is a third space effusion (such as a large amount of pleural fluid, ascites, etc.) that can not reach the stable state (no intervention treatment is needed after the removal of the drainage tube), and only a small amount of effusion on imaging and without clinical symptoms can be enrolled.\n\n6.Severe infection occurred within 4 weeks before enrollment, such as severe pneumonia, bacteremia, infectious complications, requiring hospitalization; fever of unknown cause\\> 38.5℃ within 2 weeks before enrollment (fever caused by the tumor according to the investigator); 2 weeks of enrollment (except in cases of prophylactic antibiotics).\n\n7.Severe cardiovascular and cerebrovascular disease. 8.Patients with known or suspected interstitial pneumonia except only interstitial changes on imaging.\n\n9.Prior history of clear neurological or psychiatric disorders, including epilepsy and dementia.\n\n10.Presence of non-healing wounds (severe, non-healing or split), uncured fractures.\n\n11.Adverse events due to prior treatment prior to enrollment did not return to NCI-CTCAE level 1 (except for alopecia and enrollment criteria; except AEs not affecting the study medication).\n\n12.Malignant tumors other than the primary tumor within the 5 years before enrollment, except those with low risk of metastasis and death: adequately treated cervical carcinoma in situ, skin basal cells or squamous cell carcinoma, etc.\n\n13.Combined with active hepatitis B (hepatitis B surface antigen positive and HBV DNA 500 IU \u002F mL), hepatitis C (hepatitis C antibody positive, and HCV-RNA above the lower limit of detection of the analytical method). Those known to have acquired immunodeficiency syndrome or test positive for HIV, and those infected with active syphilis. Subjects with active tuberculosis or a history of active tuberculosis infection within 48 weeks before screening, with or without treatment.\n\n14.Known to be allergic to any component of HRS-4642; allergic to any component of nytuzumab or other monoclonal antibody \u002F fusion proteins, albumin paclitaxel, gemcitabine.\n\n15.By the investigator, the patient had other factors that might affect the study results or lead to the forced termination of the study.",{"count":110,"type":21},133,[112],"PHASE2","This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.",[115],"Metastatic Pancreatic Carcinoma","2026-06-01",{"date":118,"type":35},"2026-06-03",{"date":120,"type":35},"2025-03-25",{"date":122,"type":21},"2028-02-01",{"name":41,"class":42},2,{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":132,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":43},"100640577","effects-of-rectal-indomethacin-suppository-on-postoperative-crbd-in-patients-undergoing-lrp-100640577","NCT07607990","Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP","Effects of Rectal Indomethacin Suppository on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Laparoscopic Radical Prostatectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 80 years old (inclusive);\n2. American Society of Anesthesiologists (ASA) physical status classification Class I-III;\n3. Undergoing elective laparoscopic radical prostatectomy under general anesthesia;\n4. Having a clear understanding of the study, voluntarily participating, and providing informed consent signed by themselves or their family members.\n\nExclusion Criteria:\n\n1. Pre-existing bladder diseases, such as overactive bladder (frequency of micturition \\> 3 times per night or \\> 8 times within 24 hours), neurogenic bladder, and bladder outlet obstruction;\n2. Postoperative status of pelvic organs or spine that affects bladder function;\n3. Postoperative status of total proctocolectomy;\n4. Severe cardiac insufficiency (activity tolerance \\\u003C 4 METs) or clearly diagnosed coronary heart disease;\n5. Clearly diagnosed chronic obstructive pulmonary disease (COPD) or a history of asthma;\n6. Hepatic insufficiency with Child-Pugh Class C;\n7. Chronic kidney disease requiring dialysis;\n8. Active peptic ulcer\u002Fhemorrhagic disease;\n9. Body mass index (BMI) ≤ 18 kg\u002Fm² or ≥ 28 kg\u002Fm²;\n10. Chronic analgesic abuse;\n11. Use of other nonsteroidal anti-inflammatory drugs (NSAIDs) within one week;\n12. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs);\n13. Mental or neurological disorders that prevent the completion of rating scales; or cognitive impairment resulting in the loss of capacity for civil conduct.","MALE","80 Years",{"count":135,"type":21},130,[24],"The postoperative incidence of catheter-related bladder discomfort (CRBD) ranges from 47% to 95%. It increases postoperative pain and agitation, thus requiring early intervention. Although a variety of drugs are used for the prevention or treatment of CRBD, the adverse reactions of most of these drugs have limited their clinical application. In long-term clinical practice, we found that indomethacin suppository has a good therapeutic effect on the discomfort of pelvic-related organs caused by nociceptive stimulation. However, its preventive effect on CRBD has not been reported yet. We hypothesized that indomethacin suppository has a preventive effect on postoperative CRBD. To verify this hypothesis, patients undergoing laparoscopic radical prostatectomy were enrolled in the study. Patients in the intervention group received 50 mg of indomethacin suppository via the rectal route immediately after surgery, while those in the control group received no treatment. The severity of CRBD, pain scores, consumption of analgesics, other perioperative adverse reactions, and patient satisfaction were observed and recorded at 0, 1, 2, and 6 hours after surgery.",[139,140,141],"Prostate Cancer (Post Prostatectomy)","Perioperative Anesthetic","Catheter-related Bladder Discomfort (CRBD)",[143,144,145],"catheter-related bladder discomfort","CRBD","radical prostatectomy","2026-05-25",{"date":148,"type":35},"2026-05-27",{"date":150,"type":35},"2026-01-01",{"date":152,"type":21},"2026-12-31",{"name":41,"class":42},{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":166,"conditions":167,"keywords":173,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":43},"100588144","early-phase-1-cdh17-car-t-therapy-in-advanced-malignant-solid-tumors-100588144","NCT06937567","CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors","Exploratory Study on the Safety and Preliminary Efficacy of UCLH80-1 Cells in Patients With CDH17-Positive Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* Histopathologically confirmed malignant solid tumors, including but not limited to colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract tumors.\n* Patients must have failed standard treatments, be intolerant to standard treatments, or lack effective treatment options.\n* At least one measurable lesion as defined by RECIST v1.1 criteria.\n* Tumor tissue must be available either from prior tumor biopsy or by providing new tumor specimens.\n* Tumor specimens must be confirmed as CDH17-positive by immunohistochemistry (IHC) or immunocytochemistry (ICC) staining.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival time ≥ 3 months.\n* Appropriate organ function: hematological: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹\u002FL. Hemoglobin (HGB) ≥ 80 g\u002FL; Platelet count (PLT) ≥ 75 × 10⁹\u002FL. Liver Function: aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤ 3.0 × ULN (≤ 5.0 × ULN for patients with primary liver tumors or liver metastases); total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN for patients with primary liver tumors or liver metastases; ≤ 3 × ULN for Gilbert's syndrome with direct bilirubin ≤ 1.5 × ULN). Coagulation: international normalized ratio (INR) ≤ 1.5 × ULN (unless on therapeutic anticoagulants); activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (unless on therapeutic anticoagulants). Renal Function: serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL\u002Fmin (based on Cockcroft-Gault formula). Cardiac Function: left ventricular ejection fraction (LVEF) ≥ 50% (confirmed by echocardiography). Pulmonary Function: resting oxygen saturation (SpO₂) \\> 92% without supplemental oxygen.\n* Female participants of childbearing potential must have a negative pregnancy test.\n* Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception during the study and for 1 year after the final cell infusion.\n* Willingness to sign the informed consent form, demonstrating understanding of the study and agreement to comply with study procedures.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding.\n* Positive hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) with peripheral HBV DNA levels above the lower limit of detection.\n* Positive hepatitis C virus (HCV) antibody with peripheral HCV RNA levels above the lower limit of detection.\n* Positive HIV antibody.\n* Positive syphilis-specific and non-specific antibody tests.\n* Non-hematological toxicity from prior treatment (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has not resolved to ≤ CTCAE grade 1 (except for hair loss and peripheral sensory neuropathy).\n* Prior allogeneic tissue or organ transplant (including bone marrow, stem cell, liver, kidney, etc.), except for transplants not requiring immunosuppression (e.g., corneal or hair transplantation).\n* Patients who have previously received CDH17 CAR-T therapy, except those who received CAR-T infusion within this study.\n* Underwent major surgery within 4 weeks prior to signing informed consent and has not fully recovered, or has a history of serious unresolved trauma.\n* Known central nervous system (CNS) metastases (with exceptions for asymptomatic brain metastases or stable clinical symptoms).\n* Severe active infections or pulmonary diseases requiring systemic corticosteroid treatment within 6 months prior to signing informed consent.\n* Symptomatic congestive heart failure (NYHA class II-IV), severe aortic stenosis, or symptomatic mitral stenosis.\n* ECG showing QTc \\> 450 ms or QTc \\> 480 ms with bundle branch block.\n* Uncontrolled hypertension (SBP ≥ 160 mmHg and\u002For DBP ≥ 100 mmHg).\n* Cerebrovascular accidents within 6 months prior to signing informed consent.\n* Active, chronic, or recurrent severe autoimmune diseases requiring immunosuppressive treatment (with exceptions).\n* Any form of primary or secondary immunodeficiency.\n* Risk of organ perforation or bleeding as judged by the investigator.\n* Severe systemic hypersensitivity reactions to study drugs\u002Fcomponents. - Received live attenuated vaccines within 4 weeks prior to signing informed consent.\n* Participated in another clinical study within 4 weeks prior to signing informed consent.\n* History of another malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer or in situ cancers.\n* Diagnosed with neuropsychiatric disorders or any condition deemed by the investigator as unsuitable for participation.","70 Years",{"count":163,"type":21},36,[165],"EARLY_PHASE1","The investigational product used in this study, UCLH801 cells, is a CAR-T cell therapy specifically targeting CDH17. The proposed indication includes CDH17-positive advanced solid tumors, such as but not limited to colorectal cancer, gastric cancer, pancreatic cancer, biliary tract tumors, neuroendocrine tumors, ovarian cancer, and lung cancer. The primary objective of this study is to evaluate the safety and tolerability of UCLH801 cells in patients with CDH17-positive advanced malignant solid tumors. The secondary objectives include assessing the preliminary efficacy of UCLH801 cells, their pharmacokinetics and pharmacodynamics in the body, and their immunogenicity.\n\nThis study aims to observe how the infusion of UCLH801 cells affects patients 's body, including any discomfort or changes in laboratory test results. Additionally, it will evaluate whether UCLH801 cells have any effect on tumor. Furthermore, the study will investigate how UCLH801 cells are metabolized; the mechanisms through which they exert their effects, and how to develops any immune response or rejection against UCLH801 cells.",[168,169,170,171,172],"Biliary Tract Cancer","Colorectal Carcinoma","Gastric Cancer, Metastatic","Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)","Multiple Cancer",[174,175],"CAR-T","CDH17","2026-05-20",{"date":178,"type":35},"2026-05-26",{"date":180,"type":35},"2024-12-26",{"date":182,"type":21},"2028-05-30",{"name":41,"class":42},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100638397","multimodal-thermal-therapy-with-targeted-and-immunotherapy-for-untreated-unresectable-hcc-100638397","NCT07596134","Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC","Multimodal Thermal Therapy With Targeted Therapy and Immunotherapy Versus Targeted Therapy and Immunotherapy Alone for Systemically Untreated Unresectable (HCC): a Prospective, Multicenter, Open-label, Randomized Controlled Trial.","HLP1-1331","Inclusion Criteria:\n\n* • Age 18-80, regardless of gender;\n\n  * Diagnosed with unresectable HCC by imaging or histology, BCLC stage B or C;\n  * No prior systemic immunotherapy, chemotherapy, targeted therapy, or other systemic drug treatments for HCC;\n  * Presence of an image-evaluable lesion intended for ablation without prior local ablation therapy, with the maximum diameter of the target tumor ≤5 cm;\n  * Child-Pugh score ≤7;\n  * ECOG-PS score of 0-1.\n\nExclusion Criteria:\n\n* • Invasion of the main portal vein;\n\n  * Diffuse hepatocellular carcinoma;\n  * Patients with a history or current diagnosis of brain metastases whose symptoms are not fully controlled (i.e., persistent or worsening symptoms, or requiring adjustments to symptomatic treatment to maintain symptom relief);\n  * Extensive distant metastasis confirmed by imaging (e.g., chest\u002Fabdominal CT\u002FMRI, whole-body bone scan, PET-CT, etc.), including but not limited to diffuse lung metastasis, multiple bone metastases, extensive abdominal\u002Fperitoneal metastasis, or other multi-organ metastases, where the investigator assesses that the extent of metastasis may compromise the safe administration of study treatment or affect efficacy and safety evaluations;\n  * Prior local therapy with the last treatment administered less than 4 weeks before enrollment;\n  * Involvement of major blood vessels such as the hepatic vein or inferior vena cava;\n  * Uncontrolled active infection;\n  * Renal dysfunction with serum creatinine \\>176.8 μmol\u002FL or creatinine clearance \\\u003C30 mL\u002Fmin;\n  * Uncorrectable coagulation abnormalities: platelets \\\u003C50×10⁹\u002FL, prothrombin time \\>18 seconds, prothrombin activity \\\u003C40%, and uncorrectable;\n  * History of esophageal or gastric variceal bleeding without effective treatment via endoscopy, intervention, or surgery;\n  * Patients with active psychiatric disorders;\n  * Patients receiving or requiring systemic glucocorticoids (e.g., prednisone, dexamethasone) at a dose ≥10 mg\u002Fday (prednisone equivalent) or other immunosuppressive drugs (e.g., cyclosporine, tacrolimus, methotrexate) within 14 days prior to enrollment; topical, inhaled, or ophthalmic glucocorticoid use that does not affect systemic immune function may be allowed at the investigator's discretion;\n  * History or current diagnosis of malignancies other than the target tumor in this study (excluding cured low-grade malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ). For low-grade malignancies, eligibility will be determined by the investigator;\n  * Pregnant or breastfeeding women, or women of childbearing potential planning pregnancy during the study or within 3 months after treatment completion;\n  * Expected survival \\\u003C3 months;\n  * Patients deemed unsuitable for participation by the investigator.",{"count":193,"type":21},166,[24],"Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)",[197],"Unresectable Hepatocellular Carcinoma (HCC)",[199],"HCC","2026-05-19",{"date":202,"type":35},"2026-05-22",{"date":146,"type":21},{"date":205,"type":21},"2029-05-25",{"name":41,"class":42},4,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":225,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":43},"100637505","phase-2-neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases-100637505","NCT07581912","Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","FALCO","Inclusion Criteria:\n\n* The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;\n* Age: 18-80 years old, PS score 0-1;\n* Colorectal adenocarcinoma diagnosed by histopathology, preoperative staging: T4N0-2M0, T3N2M0, T0-4N0-2M1a (with metastatic lesions present, requiring MDT evaluation as resectable); PMMR\u002FMSS, KRAS G12C mutation, and both NRAS and BRAF wild-type\n* Locally advanced colorectal cancer requires initial diagnosis of patients who have not received systematic treatment in the past. Patients with resectable metastatic lesions are required to have not received targeted therapy in the past, and new metastases after adjuvant therapy can be included in this study.\n* The main organ functions well and meets the following criteria:\n\n  1. Blood routine examination criteria (corrected for no blood transfusion or use of hematopoietic stimulating factor drugs within 7 days before screening): hemoglobin (HGB) ≥ 90g\u002FL (if chronic anemia is caused by chronic blood loss from the tumor and the researcher evaluates the stability of vital signs, it can be included in the group); absolute neutrophil count (NEUT) ≥ 1.5 × 109\u002FL; platelet count (PLT) ≥ 75 × 109\u002FL;\n  2. Biochemical tests must meet the following standards: total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN) (Gilbert syndrome subjects, ≤ 3 × ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; serum creatinine (CR) ≤ 1.5ULN or creatinine clearance rate (CCR) ≥ 50ml\u002Fmin.\n  3. Coagulation or thyroid function tests must meet the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR) ≤ 1.5 × ULN (without anticoagulant therapy); thyroid stimulating hormone (TSH) ≤ ULN; If there are abnormalities, T3 and T4 levels should be examined (if there is no T3 in the center, T4 can be replaced by FT3 and FT4), and if the level is normal, it can be selected.\n* Cardiac ultrasound evaluation: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\nExclusion Criteria:\n\nThose who meet any of the following criteria will not be included in this trial:\n\n* Patients with MSI-H\u002FdMMR present;\n* Patients with multiple metastases that cannot be resected;\n* Combined diseases and medical history:\n\n  1. Has had or is currently suffering from other malignant tumors within the past 3 years. The following situations can be included in the group:\n\n     Cured cervical carcinoma in situ, non melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basement membrane)\\];\n  2. Patients with active inflammatory bowel disease within the first 4 weeks of enrollment;\n  3. Uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage;\n  4. Unrelieved toxic reactions above CTCAE grade 1 caused by any previous anti-tumor treatment (excluding hair loss and ≤ grade 2 neurotoxicity caused by oxaliplatin);\n  5. Within 4 weeks prior to the start of the study, any bleeding events ≥ CTCAE grade 3 occurred in patients with unhealed wounds, ulcers, or fractures;\n  6. History of arterial\u002Fvenous thrombotic events within 6 months, such as cerebrovascular accidents (including transient ischemic attacks, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;\n  7. Individuals with a history of substance abuse involving psychotropic drugs who are unable to quit;\n  8. Subjects with any severe and\u002For uncontrolled diseases, including: uncontrolled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg despite standard antihypertensive treatment); myocardial ischemia or myocardial infarction ≥grade 2, arrhythmia (QTc ≥450 ms in males, QTc ≥470 ms in females, and ≥grade 2 congestive heart failure (New York Heart Association (NYHA) classification); active or uncontrolled severe infections (≥CTC AE grade 2 infection); cirrhosis, active hepatitis\\*; (\\*Active hepatitis \\[Hepatitis B reference: HBsAg positive and HBV DNA positive (\\>2500 copies\u002FmL or \\>500 IU\u002FmL); Hepatitis C reference: HCV antibody positive and HCV viral load exceeding the upper limit of normal\\] Note: For subjects meeting enrollment criteria, those with hepatitis B surface antigen positive or hepatitis B core antibody positive, or hepatitis C patients, must receive continuous antiviral treatment to prevent viral activation); renal failure requiring hemodialysis or peritoneal dialysis; history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or organ transplantation history; poorly controlled diabetes (fasting blood glucose (FBG) \\>10 mmol\u002FL); urinalysis indicating proteinuria ≥++, and confirmed 24-hour urine protein quantification \\>1.0g; a history of confirmed neurological or psychiatric disorders requiring treatment, including epilepsy or dementia.\n* Tumor-related symptoms and treatment: Previously received targeted drug therapy (including G12C inhibitors, bevacizumab, etc.);\n* According to the investigator's judgment, subjects with serious diseases that pose a significant risk to their safety or affect the completion of the study, or those deemed ineligible for enrollment due to other reasons.","85 Years",{"count":217,"type":21},40,[112],"Background：KRAS mutations are the most common genetic alterations in colorectal cancer (CRC), associated with aggressive tumor biology and poor prognosis. For metastatic CRC harboring KRAS mutations, first-line standard treatment is chemotherapy plus bevacizumab. However, its anti-angiogenic effects contraindicate perioperative use. KRAS G12C, the first druggable KRAS target, accounts for \\~3% of CRC KRAS mutations. KRAS G12C inhibitor monotherapy shows efficacy in post-standard-therapy metastatic CRC, while combination with RAS-MAPK pathway blockade demonstrates superior efficacy. Based on promising frontline data combining KRAS G12C inhibitors with anti-EGFR antibodies in metastatic CRC, we evaluate neoadjuvant fulzerasib plus cetuximab N01 in locally advanced KRAS G12C-mutated CRC, with or without resectable metastases.\n\nMethods：Single-arm, multicenter, phase II trial (N=40). Eligibility: age 18-80 years, ECOG 0-1, histologically confirmed colorectal adenocarcinoma (stages T4N0-2M0, T3N2M0, T0-4N0-2M1a \\[resectable metastases confirmed by multidisciplinary discussion\\]), KRAS G12C mutation, NRAS\u002FBRAF wild-type, pMMR\u002FMSS. Neoadjuvant therapy: fulzerasib (qd, po, d1-28) plus cetuximab N01 (500 mg\u002Fm², IV, q2w) for 2 months. Safety assessments (CBC, liver\u002Frenal function, QoL) every 2 weeks; CEA monthly. Tumor response assessed by CT chest\u002Fabdomen and rectal MRI at 2 months. Radical surgery for responders (cCR patients may choose watchful waiting). Adjuvant therapy per pathological response. Follow-up: CEA every 3 months, CT every 6 months. Primary endpoint: overall response rate (pCR or cCR). Secondary endpoints: ORR, 1-year DFS, 3-year DFS, QoL. RECIST v1.1 for disease assessment; NCI-CTCAE v5.0 for adverse events.\n\nHypothesis：This chemotherapy-free neoadjuvant regimen combining a KRAS G12C inhibitor with cetuximab N01 may enhance perioperative safety and improve prognosis and quality of life in patients with KRAS G12C-mutated CRC.",[221,222,223,224],"Colorectal Cancer","KRAS G12C Mutant Advanced Solid Tumors","Fulzerasib","Cetuximab N01",[226,227,228,229,230],"fulzerasib","cetuximab N01","chemotherapy-free","KRAS G12C mutant","locally advanced colorectal cancer","2026-05-11",{"date":233,"type":35},"2026-05-12",{"date":235,"type":35},"2026-04-30",{"date":237,"type":21},"2031-12",{"name":41,"class":42},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":255,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":72},"100616588","high-flow-nasal-cannula-for-preventing-hypoxia-during-sedated-endoscopy-in-high-risk-obstructive-sleep-apnea-patients-100616588","NCT07307560","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients: A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* STOP-Bang score ≥5.\n* Scheduled for sedated gastrointestinal endoscopy (gastroscopy, colonoscopy, or combined gastroscopy + colonoscopy).\n* The estimated duration of the procedure does not exceed 45 minutes.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Coagulation disorders or bleeding tendency (e.g., oral\u002Fnasal bleeding risk, mucosal injury, space-occupying obstructions).\n* Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature \\>37.5°C).\n* Chronic obstructive pulmonary disease or other acute\u002Fchronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air.\n* Severe organ dysfunction, including: Cardiac insufficiency (\\\u003C4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV.\n* Confirmed pregnancy or current breastfeeding.\n* Known allergy to sedatives (e.g., propofol) or medical adhesives.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator",{"count":247,"type":21},600,[24],"Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests that High-Flow Nasal Cannula (HFNC) may lower the incidence of hypoxemia, evidence remains limited and inconsistent in studies specifically targeting high-risk OSA populations. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxia during sedated gastrointestinal endoscopy in patients identified as high-risk for OSA.",[251,252,253,254],"Hypoxia","Esophageal Cancer","Gastric Cancer (Diagnosis)","Obstructive Sleep Apnea (OSA)",[256,251,254,257],"Sedation","Gastrointestinal Endoscopy","2026-05-01",{"date":260,"type":35},"2026-05-04",{"date":262,"type":35},"2025-12-21",{"date":264,"type":21},"2026-12-01",{"name":41,"class":42},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":283,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":207},"100636237","effect-of-high-flow-nasal-cannula-oxygen-therapy-on-hypoxemia-in-pediatric-sedated-bronchoscopy-100636237","NCT07563075","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 1 year ≤ age ≤ 6 years,\n* Weight ≥ 10 kg,\n* Undergoing elective sedated bronchoscopy,\n* Expected procedure duration ≤ 45 minutes,\n* Written informed consent obtained from the subject's legal guardian.\n\nExclusion Criteria:\n\n* preoperative SpO₂ \\\u003C 95% on room air,\n* Already sedated and tracheally intubated,\n* Known history of pneumothorax, known congenital or acquired upper airway abnormalities (e.g., nasopharyngeal structural anomalies), or history of difficult airway,\n* Coagulation disorders or predisposition to oral\u002Fnasal bleeding, mucosal injury, or space-occupying lesions,\n* Severe cardiac insufficiency (\\\u003C 4 METs), severe renal insufficiency (requiring dialysis), diagnosed severe hepatic insufficiency, Increased intracranial pressure, or ASA classification ≥ IV,\n* Allergy to propofol or sufentanil,\n* Multiple traumatic injuries,\n* Current participation in another clinical trial,\n* Other conditions deemed unsuitable by the investigator.","1 Year","6 Years",{"count":276,"type":21},430,[24],"Due to children's lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified breathing gas with a precisely controllable oxygen concentration, at flow rates exceeding the patient's peak inspiratory flow, directly via unsealed nasal prongs. It is a simple, comfortable, effective, and non-invasive respiratory support method that has been widely adopted in clinical practice. However, the effectiveness of HFNC in pediatric sedation remains unclear. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxemia during sedated bronchoscopy in pediatric patients.",[280,281,282],"Hypoxemia","Pneumonia","Pulmonary Neoplasm",[284,280,256,285,286],"Bronchoscopy","Pediatric","High-flow nasal cannula","2026-04-28",{"date":258,"type":35},{"date":290,"type":21},"2026-04-01",{"date":292,"type":21},"2027-03-31",{"name":41,"class":42},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":300,"maxAge":81,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":43},"100630417","early-phase-1-safety-and-efficacy-of-metabolically-armed-gpc3-car-t-cells-injection-meta10-gpc3-in-patients-with-unresectable-recurrentmetastatic-hepatocellular-carcinoma-100630417","NCT07487402","Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent\u002FMetastatic Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Age \\>18 years and ≤75 years, male or female.\n* Histologically confirmed recurrent or metastatic hepatocellular carcinoma (HCC) that is not amenable to surgical resection.\n* At least one measurable target lesion according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n* Tumor tissue must test positive for GPC3 expression by immunohistochemical (IHC), defined as \\> 25% of tumor cells staining for GPC3 in the pathological specimen. Preferably, the target lesion sample should be used, including freshly obtained tumor tissue or archival tissue samples deemed acceptable by the investigator.\n* Expected survival ≥ 12 weeks.\n* Child-Pugh class A.\n* Eastern Cooperative Oncology Group (ECOG) performance status was 0-1.\n* For subjects who are HBsAg or HBcAb positive, HBV-DNA must be \\\u003C 2 000 IU\u002FmL; HBsAg-positive patients must receive antiviral therapy according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition).\n* Adequate venous access for leukapheresis or venous blood collection.\n* Hematologic parameters: WBC ≥ 2.5 × 10⁹\u002FL, platelets ≥ 60 × 10⁹\u002FL, Hb ≥ 9.0 g\u002FdL, lymphocytes ≥ 0.4 × 10⁹\u002FL.\n* Biochemical parameters: Serum albumin ≥ 30 g\u002FL; Lipase and amylase ≤ 1.5 × ULN; serum creatinine ≤ 1.5 × ULN and estimated creatinine clearance ≥ 40 mL\u002Fmin; ALT and AST ≤ 5 × ULN; serum total bilirubin ≤ 2.5 × ULN; prothrombin time ≤ 4s longer above normal.\n* Women or childbearing potential must have a negative serum pregnancy test within 14 days before CAR-T cell infusion and agree to use effective contraception for 12 months after infusion. Male subjects with partners of childbearing potential must having undergone a vasectomy or agree to use reliable contraception during the study period.\n* Ability to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women of childbearing potential who test positive on a pregnancy test during the screening period).\n* Active hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection; seropositivity for Human Immunodeficiency (HIV) or syphilis.\n* Any uncontrolled active infection, including but not limited to active pulmonary tuberculosis.\n* Therapeutic doses of corticosteroids must be discontinued at least 2 weeks prior to Meta10-GPC3 infusion; any immunosuppressive medications must be discontinued at least 4 weeks before signing the informed consent form.\n* History of hypersensitivity to immunotherapy or related agents, β-lactam antibiotics, or other severe allergic reactions.\n* History or presence of hepatic encephalopathy.\n* Clinically significant ascites, defined as ascites detectable on physical examination or requiring therapeutic intervention (excluding ascites detected only by imaging that does not require intervention).\n* Imaging showing that HCC occupies ≥ 50 % of normal liver volume, or presence of tumor thrombus in the main portal vein or inferior vena cava.\n* Clinically significant central-nervous-system (CNS) disorders (excluding subjects with CNS HCC metastases).\n* Active or decompensated cardiac illness (requiring hospitalization or surgical intervention within the past 6 months), or poorly pression ≥ 160\u002F100 mmHg uncontrolled with medication. Stable coronary artery disease or well-controlled hypertension is allowed.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Prior organ transplantation or currently on an organ transplant waiting list (including but not limited to liver transplantation).\n* Any anti-HCC therapy within 2 weeks prior to leukapheresis or blood collection, including but not limited to surgical resection, interventional therapy, radiotherapy, chemotherapy, or immunotherapy.\n* History or concurrent presence of other malignancies, except for the following: surgically removed non-melanoma skin cancer, cured cervical carcinoma in situ, localized prostate cancer, low-stage bladder cancer, ductal carcinoma in situ of the breast, or any malignancy without recurrence or treatment within the past 2 years.\n* Other severe medical conditions, including but not limit to: poorly controlled diabetes (post-treatment HbA1c \\> 7 %), severe cardiac dysfunction (LVEF \\\u003C 45 %), myocardial infarction, unstable angina, or unstable arrhythmia within 6 months, pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease, forced expiratory volume in 1 second (FEV1) \\\u003C 60 %, gastric ulcer, history of gastrointestinal bleeding, documented bleeding diathesis, uncontrolled thrombotic events, major bleeding, or DVT within 12 months prior to informed consent.\n* Active neurological autoimmune or inflammatory disorders (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).\n* History of QT-interval prolongation or severe cardiac disease.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation in the study (e.g., poor compliance).","19 Years",{"count":302,"type":21},27,[165],"A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent\u002FMetastatic Hepatocellular Carcinoma.",[306],"Hepatocellular Carcinoma (HCC)",[308,309,310],"Meta10-GPC3","unresectable recurrent\u002Fmetastatic hepatocellular carcinoma","IL-10","2026-04-16",{"date":313,"type":35},"2026-04-21",{"date":315,"type":21},"2026-03-30",{"date":317,"type":21},"2029-04-15",{"name":41,"class":42},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":326,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":344},"100599884","china-colorectal-cancer-screening-trial-1-c-cost1-100599884","NCT07090291","China Colorectal Cancer Screening Trial 1 (C-Cost1)","China Colorectal Cancer Screening Trial 1 (C-Cost1): Colonoscopy Versus FIT Versus FIT Plus Blood Test in the Average Risk Population","Inclusion Criteria:\n\n1. Age: 45-74 years old;\n2. In good general condition, with normal mental state and voluntarily signing the informed consent form;\n\nExclusion Criteria:\n\n1. Personal history of colorectal cancer or precancerous lesions;\n2. History of previous colonrectal resection surgery;\n3. Diagnosed with cancer before enrollment or currently receiving any cancer-related treatment;\n4. Having received colonoscopy, flexible sigmoidoscopy, CT colonography and other examinations within the past 5 years;\n5. Having received FIT or FIT-sDNA or cfDNA test within the past 1 year;\n6. Symptomatic lower gastrointestinal diseases or symptoms suggesting the need for diagnostic colonoscopy for confirmation;\n7. Accompanied by severe diseases that are not suitable for colorectal cancer screening;","45 Years","74 Years",{"count":329,"type":21},60300,[24],"Colorectal cancer (CRC) is one of the most common malignancies in China. Currently, its incidence rate is increasing at a rate of 4% per year, exceeding the global annual average growth rate. Screening and early diagnosis of colorectal cancer and precancerous lesions are key measures to reduce the disease burden of colorectal cancer in China. In previous clinical studies, colorectal cancer screening in high risk population received extensive attention. However, it cannot be ignored that the majority of sporadic colorectal cancers occur in the average risk population. Therefore, there is an urgent need to develop new approach for colorectal cancer screening in the average risk population in China.\n\nFecal Immunochemical Testing (FIT) initial screening followed by diagnostic colonoscopy is widely recommended by colorectal cancer screening guidelines worldwide. The current colorectal cancer screening approach faces challenges including limited sensitivity of initial screening technologies and insufficient population coverage in organized screening programs in China. As initial screening technologies, non-invasive blood tests which detects cfDNA methylation have been reported to have higher accuracy than FIT in detecting colorectal cancer. However, There is a lack of randomized controlled trials (RCTs) comparing the effectiveness of colonoscopy, FIT and FIT plus blood test for colorectal cancer screening.\n\nIn China Colorectal Cancer Screening Trial 1 (C-Cost1), we propose to perform a multicenter, cluster randomized, parallel group trial directly comparing colonoscopy with FIT and with FIT plus blood test in the average risk population in China. The main research hypotheses are: (1) The screening protocol of FIT group (Group B) is non-inferior to the colonoscopy group (Group A) in the colorectal cancer mortality rate at 10 years; (2) The screening protocol of FIT plus blood test group (Group C) is non-inferior to the colonoscopy group (Group A) in the colorectal cancer mortality rate at 10 years. Both of the two hypotheses should be met.",[221,333],"Advanced Adenoma",[335],"FIT; FIT plus blood test; cfDNA methylation; Colorectal cancer; Advanced colorectal adenoma; Early screening; Average risk population","2026-04-12",{"date":338,"type":35},"2026-04-14",{"date":340,"type":35},"2025-08-08",{"date":342,"type":21},"2035-07",{"name":41,"class":42},7,{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":43},"100413241","phase-2-cd19-car-t-therapy-for-patients-with-newly-diagnosed-high-risk-large-b-cell-lymphoma-100413241","NCT04661020","CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma","Clinical Trial for the Efficacy and Safety of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma","Inclusion Criteria:\n\n1. Age no less than 18, no gender limit;\n2. Newly diagnosed high-risk Large B-cell Lymphoma, which was defined by the following criteria: (1) DLBCL not otherwise specified with an IPI score ≥3 at diagnosis, (2) high grade B-cell lymphoma (HGBL) with gene rearrangement of MYC and BCL2 and\u002For BCL6, (3) HGBL not otherwise specified;\n3. Confirmed CD19 and CD20 postive expressions in lymphoma cells\n4. ECOG score 0-2;\n5. Total bilirubin ≤ 51 umol\u002FL, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol\u002FL;\n6. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;\n7. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;\n8. Estimated survival time ≥ 3 months;\n9. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Central nervous system involvement by lymphoma；History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;\n2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n3. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);\n4. Active infection of hepatitis B virus or hepatitis C virus;\n5. Previously treated with any CAR-T cell product or other genetically modified T cell therapies;\n6. Insufficient amplification capacity in response to CD3\u002FCD28 co-stimulus signal (\\\u003C5 times) ;\n7. Other uncontrolled diseases that were not suitable for this trial;\n8. Patients with HIV infection;\n9. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.",{"count":217,"type":21},[112],"A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma",[356],"Large B-Cell Lymphoma (LBCL)",[358,359,174],"CD19","Large B-Cell Lymphoma",{"date":361,"type":35},"2026-04-07",{"date":363,"type":35},"2020-12-03",{"date":365,"type":21},"2026-12-20",{"name":41,"class":42},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":374,"minAge":18,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":384,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":43},"100629908","teas-combined-with-triple-antiemetic-drugs-to-prevent-ponv-in-high-risk-patients-100629908","NCT07480785","TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients","Transcutaneous Electrical Acupoint Stimulation Combined With Triple Antiemetic Drugs for Postoperative Nausea and Vomiting in High-Risk Patients: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Women scheduled for laparoscopic surgery ；\n* Aged 18-65 years；\n* ASA Class I-III；\n* Apfel score ≥ 3 (female sex, non-smoker, history of PONV and\u002For motion sickness).\n\nExclusion Criteria:\n\n* Patients with a history of allergy to the investigational drug or contraindications；\n* Long-QT syndrome ；\n* Pregnancy, lactation, or menstruation ；\n* Current smoker；\n* Nausea\u002Fvomiting or use of antiemetics, opioids, or systemic corticosteroids within 24 h before surgery；\n* Requirement for post-operative sedation and mechanical ventilation ；\n* Severe renal or hepatic impairment ；\n* Psychiatric or neurological disorder ；\n* Vertebrobasilar insufficiency；\n* Vestibular disease；\n* Language or communication barrier ；\n* Skin lesion or infection at the acupoint stimulation site ；\n* Upper-limb nerve injury ；\n* Implanted cardiac pacemaker or defibrillator ；\n* Participation in another clinical trial within the past 4 weeks.","FEMALE","65 Years",{"count":377,"type":21},780,[24],"The goal of this clinical trial is to evaluate the effects of transcutaneous electrical acupoint stimulation (TEAS) combined with triple antiemetics for postoperative nausea and vomiting (PONV) in high-risk patients.\n\nThe primary question it seeks to answer is:\n\nDoes TEAS combined with triple antiemetics further reduce the incidence of PONV in high-risk subjects? Researchers will compare active TEAS with sham stimulation to determine whether the addition of TEAS to dexamethasone, palonosetron, and droperidol lowers the PONV rate beyond that achieved by the triple-drug prophylaxis alone.",[381,382,383],"Uterine Fibroids (Leiomyoma)","Ovarian Tumors","Gallstones",[385,386,387],"postoperative nausea and vomiting","transcutaneous electrical acupoint stimulation","high-risk patients with PONV","2026-03-15",{"date":390,"type":35},"2026-03-18",{"date":392,"type":35},"2026-01-16",{"date":394,"type":21},"2027-10-31",{"name":41,"class":42},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":402,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":411,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":43},"100629851","a-phase-ii-clinical-two-stage-study-of-transcranial-magnetic-stimulation-in-preventing-postoperative-delirium-in-elderly-patients-after-urological-surgery-100629851","NCT07480044","A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery","Inclusion Criteria:(1) Age ≥ 60 years old; (2) Patients scheduled for elective urological surgery under general anesthesia with tracheal intubation; (3) ASA classification I - III; (4) Estimated operation duration ≥ 2 hours; (5) Informed consent from the patient or their guardian; (6) Proficient in communicating in Chinese. -\n\nExclusion Criteria:(1) Patients with permanent lack of autonomy (2) Not applicable for delirium assessment: including language disorders, deafness, blindness or aphasia, coma (3) With treatment abandonment or brain death (4) Known pregnancy or lactation (5) Unable to obtain consent according to national regulations (6) Patients forcibly hospitalized by regulatory authorities (compulsory measures) (7) With cardiac pacemaker or stent implantation (8) Patients with delirium (9) Patients with known brain lesions (10) Patients with known epilepsy history, having taken drugs that can cause epileptic seizures, having metal implants in the neck or brain, or having cerebral hemorrhage ，Acute phase, acute infectious diseases (11) Habitual treatment with antipsychotic drugs (12) Received antipsychotic drug treatment in the ICU before enrollment (13) Patients with severe liver dysfunction (Child-Pugh C grade) (14) Patients with severe kidney dysfunction (requiring dialysis before surgery) (15) Severe heart failure (METS \\\u003C 4) (16) Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery;\n\n\\-","60 Years",{"count":404,"type":21},220,[24],"Cases were included based on the inclusion and exclusion criteria, and induction, maintenance, and recovery were conducted in accordance with the standard protocol for general anesthesia. After tracheal intubation and before tracheal tube removal at the end of the surgery, the parameters for iTBS stimulation frequency and duration were as follows: intensity was 80% of the active movement threshold, with 3 pulses per cluster at 50Hz, a frequency of 5Hz, 30 clusters of 10 pulses each, an 8 - second interval, and a single 600 - pulse; the 8 - shaped coil was connected to the electrodes in the designated head area (left frontal lobe cortex).Observation contents: Whether there is postoperative delirium and its severity: 3D - CAM assessment scale, DMAS assessment scale; awakening time, extubation time, PACU stay time, hospital stay time; 1 - 7 days after surgery or before discharge, POD assessment and pain - sleep assessment, the first time getting out of bed; postoperative complications; adverse reactions; adverse events, and so on.",[408,409,410],"Postoperative Delirium (POD)","Prostate Cancer","Kidney Tumor",[412,413,414],"Transcranial Magnetic Stimulation Device","elderly patients","Postoperative Delirium","2026-03-13",{"date":390,"type":35},{"date":418,"type":21},"2026-03-20",{"date":420,"type":21},"2028-12-01",{"name":41,"class":42},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":43},"100570738","early-phase-1-safety-and-efficacy-of-metabolically-armed-cd19-car-t-cells-meta10-19-in-the-treatment-of-moderate-to-severe-active-sle-clinical-research-100570738","NCT06711146","Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research","Inclusion Criteria:\n\n* All subjects or guardians must sign an informed consent form approved by the Ethics Committee in person before commencing any screening process;\n* Be over 18 years of age, male or female;\n* A diagnosis of SLE according to the 2012 systemic lupus international collaborating clinics(SLICC);\n* The history of SLE prior to screening was at least 6 months, and the disease remained active at least 2 months after the use of a stable standard SLE regimen prior to screening:\n\n  1. Conventional regimens for SLE are corticosteroids and one or more immunomodulatory drugs over 6 months；\n  2. Oral corticosteroids must meet the following requirements:\n\n     * Prednisone (or equivalent) ≥7.5 mg\u002F day, and ≤60 mg\u002F day；\n     * There is no minimum daily dose requirement for corticosteroids when used in combination with immunosuppressants；\n     * At least 8 weeks of treatment prior to screening, and the dose must be kept stable for \\> 2 weeks.\n* Screening is positive for antinuclear antibodies, and\u002For anti-DS-DNA antibodies, and\u002For anti-Smith antibodies；\n* SELENA-SLEDAI score ≥8 during the screening period. Score ≥6 for SELENA-SLEDAI clinical symptoms (except for low complement and\u002For anti-DS-DNA antibodies) if low complement and\u002For anti-DS-DNA antibody score is present；\n* Women of childbearing age and all male patients must consent to use a effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR T cells in vivo;\n* CD19 expression was positive by or flow cytometry ;\n* Organ function：\n\n  1. Complete blood count (CBC) test \\[the following criteria should be met within 24 hours prior to apheresis, and supportive treatment such as transfusion, platelet transfusion, cell growth factor (except recombinant erythropoietin) should be avoided within 7 days prior to detection\\]\n\n     * Lymphocyte count ≥ 0.5×109\u002FL (except for those receiving bridging chemotherapy);\n     * Platelet count ≥ 25×109\u002FL;\n     * Hemoglobin ≥ 70.0 g\u002FL\n  2. Blood Biochemistry:\n\n     * Serum creatinine (Scr) ≤ 1.5 x ULN, or\n     * endogenous creatinine clearance ≥ 40 mL\u002Fmin (using Cockcroft-Gault formula);\n     * alanine aminotransferase (ALT) ≤ 2.5 x ULN;\n     * aspartate aminotransferase (AST) ≤ 2.5 ×ULN;\n     * Total bilirubin (TBIL) ≤ 2 ×ULN; Subjects with total bilirubin \\\u003C 3 × ULN and direct bilirubin \\\u003C 1.5× ULN with Gilbert-.Meulengracht syndrome could be included;\n     * Serum lipase and amylase ≤ 1.5×ULN;\n     * Alkaline phosphatase (ALP) ≤ 2.5 ×ULN;\n     * In case of bone or liver metastasis, AST, ALT and ALP ≤ 5 ×ULN;\n     * Prothrombin time (PT) extended ≤ 4 s, fibrinogen ≥ 1 g\u002FL, activated partial thromboplastin time (APTT) ≤ 1.5 ×ULN;\n  3. Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) \\> 91% in indoor air environment..\n* Hemodynamic stability was determined by echocardiography or multichannel radionuclide angiography (MUGA) and LVEF ≥45％.\n\nExclusion Criteria:\n\n* Severe lupus nephritis (defined as proteinuria \\> 6 g\u002F24h or serum creatinine \\> 2.5 mg\u002FdL or 221 μmol\u002FL), treatment with active nephritis with Prohibited drugs, hemodialysis, or prednisone ≥100 within 8 weeks prior to screening mg\u002Fd or equivalent glucocorticoid therapy ≥14 days.\n* Prior to screening, other lupus crises, such as active central nervous system lupus, severe hemolytic anemia, severe thrombocytopenic purpura, severe agranulocytosis, severe myocardial damage, severe lupus pneumonia or pulmonary hemorrhage, severe lupus hepatitis, and severe vasculitis.\n* Clinically significant central nervous system diseases or pathological changes not caused by lupus prior to screening, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions\u002Fconvulsions, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.\n* Combined with other autoimmune diseases, systematic treatment is needed.\n* History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell\u002Fbone marrow transplantation.\n* IgA deficiency was present during screening (serum IgA level \\\u003C 10 mg\u002FdL).\n* Other conditions that the investigator considered should not be enrolled in this clinical study.",{"count":163,"type":21},[165],"A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Moderate to Severe Active Systemic Lupus Erythematosus",[432],"Systemic Lupus Erythematosus",[434,435,432],"Meta10-19","CAR-T Cells Therapy","2026-03-10",{"date":415,"type":35},{"date":439,"type":35},"2024-12-24",{"date":441,"type":21},"2027-04-05",{"name":41,"class":42},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":457,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":72},"100628850","video-double-lumen-tube-for-secondary-pulmonary-resection-100628850","NCT07467005","Video Double-Lumen Tube for Secondary Pulmonary Resection","Video Double-Lumen Tube for Secondary Pulmonary Resection: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* History of previous pulmonary resection.\n* Scheduled for elective pulmonary surgery.\n* Planned to receive a left-sided double-lumen tube.\n* ASA physical status I-III.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Preoperatively predicted difficult airway (Mallampati ≥ III, Cormack-Lehane ≥ III).\n* Acute respiratory distress syndrome (ARDS) or respiratory failure within the past 3 months.\n* Uncontrolled asthma.\n* Confirmed pregnancy or current breastfeeding.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator.",{"count":451,"type":21},500,[24],"During thoracic surgery, double-lumen endotracheal intubation with one-lung ventilation is routinely performed to optimize surgical exposure, facilitate operative manipulation, and prevent iatrogenic lung injury. In patients undergoing repeat pulmonary surgery, prior lung resection may lead to pleural adhesions and tracheobronchial distortion, which substantially increase the difficulty of bronchial intubation. Even with experienced operators, the malposition rate of conventional double-lumen tubes remains high. The video double-lumen tube enables continuous visualization of the trachea and carina during insertion, positioning, and one-lung ventilation, allowing real-time airway monitoring. However, no clinical studies have specifically investigated airway management in patients undergoing redo pulmonary surgery. This study aimed to evaluate the efficacy and safety of the video double-lumen tube during anesthesia in patients undergoing secondary pulmonary resection.",[455,456],"Lung Cancer","Pulmonary Nodule",[458,459,460,461],"First-attempt Intubation Success Rate","One-lung Ventilation","video double-lumen tube","secondary pulmonary resection","2026-03-09",{"date":464,"type":35},"2026-03-12",{"date":466,"type":21},"2026-03-16",{"date":468,"type":21},"2027-12-05",{"name":41,"class":42},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":22,"phases":478,"briefSummary":479,"conditions":480,"keywords":483,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":493},"100606407","combination-of-combo-endoscopy-oropharyngeal-airway-and-hfnc-oxygenation-in-sedated-gastrointestinal-endoscopy-for-morbidly-obese-patients-100606407","NCT07175155","Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients","Combination of COMBO Endoscopy Oropharyngeal Airway and High-flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients: a Multicenter, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* BMI ≥ 35 kg\u002Fm².\n* Patients undergoing gastroscopy or gastrointestinal endoscopy.\n* The estimated duration of the procedure does not exceed 45 minutes.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Coagulation disorders or bleeding tendency (e.g., oral\u002Fnasal bleeding risk, mucosal injury, oropharyngeal obstruction) making oropharyngeal airway placement unsafe or unfeasible.\n* Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature \\>37.5°C).\n* Chronic obstructive pulmonary disease or other acute\u002Fchronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air.\n* Severe organ dysfunction, including: Cardiac insufficiency (\\\u003C4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV.\n* Confirmed pregnancy or current breastfeeding.\n* Known allergy to sedatives (e.g., propofol) or medical adhesives.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator.",{"count":52,"type":21},[24],"Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent airway collapse. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management.The purpose of this study is to investigate whether the combination of the COMBO Endoscopy Oropharyngeal Airway and High-Flow Nasal Cannula oxygenation reduces the incidence of hypoxemia in this population.",[280,252,481,482],"Morbidly Obese Patients","Gastric Cancer",[484,280,256,257,485],"COMBO Endoscopy Oropharyngeal Airway","high-flow nasal cannula",{"date":487,"type":35},"2026-03-11",{"date":489,"type":35},"2025-10-24",{"date":491,"type":21},"2027-08-20",{"name":41,"class":42},5,{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":501,"targetDuration":503,"studyType":504,"phases":4,"briefSummary":505,"conditions":506,"keywords":509,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":72},"100600955","development-and-validation-of-a-risk-prediction-model-for-gastric-retention-in-patients-undergoing-sedated-gastroscopy-100600955","NCT07104214","Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy","Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy: a Multicentre Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years.\n* Patients scheduled for elective sedated gastroscopy or sedated gastro-colonoscopy.\n* Participant provides informed consent.\n\nExclusion Criteria:\n\n* Acute upper gastrointestinal bleeding (active hematemesis, melena, or confirmed UGIB within 24h).\n* Emergency endoscopic procedures\n* Known pregnancy or lactation\n* Subjects deemed ineligible by investigators",{"count":502,"type":21},5000,"1 Day","OBSERVATIONAL","Gastric retention not only compromises the quality of endoscopic examination but also significantly increases the risk of reflux and aspiration in sedated patients. Aspiration of gastric contents represents a critical anesthesia-related complication during the perioperative period, carrying substantial implications for anesthetic management. With the growing volume of sedated gastroscopy procedures, predicting gastric retention has become an urgent clinical priority. This prospective study aims to establish a standardized gastric residual volume (GRV) grading system to evaluate both the volume of retained gastric contents and its contributing factors in patients undergoing upper gastrointestinal endoscopy. We will systematically assess the impact of demographic characteristics, comorbidities, and medication history on gastric emptying function. This study will facilitate establishment of an endoscopy-based simplified assessment system for gastric retention.",[507,252,508],"Gastric Cancer Stage","Gastroparesis",[510,511,508,512],"Gastric retention","Impaired gastric motility","Delayed gastric emptying",{"date":487,"type":35},{"date":515,"type":35},"2025-08-03",{"date":517,"type":21},"2026-05-31",{"name":41,"class":42},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":526,"targetDuration":4,"studyType":22,"phases":528,"briefSummary":529,"conditions":530,"keywords":535,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":43},"100495479","phase-2-serplulimab-combined-with-capeox--celecoxib-as-neoadjuvant-treatment-for-locally-advanced-rectal-cancer-100495479","NCT05731726","Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","A Phase II Study to Explore the Neoadjuvant Treatment of Serplulimab Combined With CAPEOX + Celecoxib in the Treatment of Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Male or female subjects ≧ 18 years ≦ 75 of age.\n3. Histological or cytological documentation of adenocarcinoma of the rectum.\n4. No previous any systemic anticancer therapy for rectal cancer disease.\n5. The lower margin of the tumor is less than 10cm from the anus verge.\n6. cT2N1-2M0, cT3N0-2M0, cT4N0-2M0 MSS with MRF(-) assessed by MRI.\n7. Primary tumor can be detected by CT or MRI.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n9. Eligible tumor tissues were identified for MSI\u002FMMR assays.\n10. Hepatitis B Surface Antigen (HBsAg) (-).\n11. If HBsAg (+) , HBV-DNA must be less than 2500 copies\u002FmL or 500 IU\u002FmL to be enrolled.\n12. Patients with HCV antibody (-) or HCV-RNA negative can be enrolled. Aspartate aminotransferase (AST) must be ≤ 3 x ULN for the lab. If HCV-RNA is positive, patients with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) performed ≤3×ULN could be enrolled. Patients infected with both hepatitis B virus and hepatitis C virus should be excluded (positive for HBsAg or HBcAb and positive for HCV antibodies).\n\nExclusion Criteria:\n\n1. Patients with recurrent rectal cancer or a history of pelvic radiotherapy.\n2. Patients with a history of inflammatory bowel disease.\n3. Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease (HIV1 antibody, HIV2 antibody, HTLV1 antibody positive) should be excluded.\n4. Patients who are preparing for or have previously received an organ or bone marrow transplant.\n5. History of myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms in women) in the 6 months prior to enrollment (QTc interval calculated by Fridericia formula).\n6. According to New York College of Cardiology (NYHA) standards for Grade III-IV cardiac insufficiency or cardiac color ultrasound: left ventricular ejection fraction (LVEF) \\\u003C50%.Poor hypertension control (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.\n7. Poor hypertension control (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.\n8. Patients had undergone major surgery within 28 days prior to enrollment. Patients with tumor biopsy or lymph node dissection biopsy were admitted. Patients undergoing enterostomy due to intestinal obstruction were admitted.\n9. The patients had previously been treated with other antibodies\u002Fdrugs that target immune checkpoints, such as PD-1, PD-L1, and cytotoxic T lymphocyte-associated Antigen 4 (CTLA-4).\n10. Patients are participating in other clinical studies, or plan to start this study treatment less than 14 days from the end of the previous clinical study.\n11. Uncontrolled tumor-related pain.\n12. A known history of severe allergy to any monoclonal antibody.\n13. Known to be allergic or intolerance to any oxaliplatin and capecitabine ingredients.\n14. Pregnant or lactating women.\n15. The investigators determined that the patient had other factors that might have led to the early termination of the study.",{"count":527,"type":21},50,[112],"Colorectal cancer of Mismatch Repair-proficient (pMMR)\u002F Microsatellite Stability (MSS) accounts for approximately 85% of all colorectal cancer patients, which might be insensitive to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy, such as CAPEOX regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Celecoxib, a COX-2 inhibitor, can improve the immune microenvironment and have a potential to synergy with immunotherapy. Chemotherapy can improve the immunogenicity of cancer cells that might enhance the efficacy of immunotherapy. The aim of this study is to explore whether chemotherapy and cyclooxygenase (COX) inhibitors combined with anti-PD-1 monoclonal antibody (mAb) could improve efficacy for resectable colorectal cancer patient with the pMMR\u002FMSS phenotype.",[531,532,533,534],"pMMR","MSS","MSI-L","Locally Advanced Rectal Carcinoma",[536,537,538,539,92],"Rectal cancer","Serplulimab","Celecoxib","CAPEOX","2026-03-03",{"date":542,"type":35},"2026-03-05",{"date":544,"type":35},"2023-02-22",{"date":546,"type":21},"2026-12-30",{"name":41,"class":42},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":43},"100625963","early-phase-1-clinical-study-of-syncar-100-in-the-treatment-of-relapsedrefractory-acute-b-lymphoblastic-leukemia-100625963","NCT07429461","Clinical Study of SYNCAR-100 in the Treatment of Relapsed\u002FRefractory Acute B-Lymphoblastic Leukemia","Early Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SYNCAR-100 in the Treatment of CD19-Positive Relapsed or Refractory Acute B-Lymphoblastic Leukemia (R\u002FR B-ALL)","Inclusion Criteria:\n\n* 1.Aged 18 to 75 years (inclusive), of any gender.\n* 2.Karnofsky Performance Status score ≥ 70.\n* 3.Estimated life expectancy ≥ 12 weeks.\n* 4.Positive CD19 expression on tumor cells confirmed by flow cytometry in bone marrow or peripheral blood.\n* 5.Confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) by bone marrow examination, and meeting one of the following criteria:\n* ① Refractory B-ALL: Failure to achieve complete remission (CR) after 2 courses of standard induction chemotherapy, or failure to achieve CR after first-line\u002Fmultiline salvage chemotherapy.\n* ② Relapsed B-ALL: Relapse within 12 months after the first remission, or relapse after first-line\u002Fmultiline salvage chemotherapy.\n* ③Relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT).\n* ④ For Philadelphia chromosome-positive (Ph+) patients: At least 2 lines of tyrosine kinase inhibitor (TKI) therapy have failed, or the patient is intolerant to TKI therapy, or the patient harbors the T315I mutation and is resistant to TKIs.\n* 6.Proportion of blasts and immature lymphocytes in bone marrow \\> 5% confirmed by bone marrow morphologic examination.\n* 7.No prior hematopoietic stem cell transplantation (HSCT) within 6 months before enrollment.\n* 8.Adequate organ function reserve, as defined by all of the following:\n* ① Creatinine clearance (calculated by the Cockcroft-Gault formula) \\> 60 mL\u002Fmin: Male: Creatinine Clearance = \\[(140 - Age) × Body Weight (kg)\\] \u002F \\[0.818 × Serum Creatinine (μmol\u002FL)\\] Female: Creatinine Clearance = \\[(140 - Age) × Body Weight (kg) × 0.85\\] \u002F \\[0.818 × Serum Creatinine (μmol\u002FL)\\]\n* ② Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 times the upper limit of normal (ULN) ; for patients with hepatic metastasis, AST and ALT ≤ 5 times the upper limit of normal (ULN) .\n* ③Serum total bilirubin \\\u003C 1.5 times the upper limit of normal (ULN) ; for patients with Gilbert's syndrome, total bilirubin ≤ 3 times the upper limit of normal (ULN) .\n* ④ Absolute lymphocyte count (ALC) ≥ 0.1 × 10\\^9\u002FL.\n* ⑤Left ventricular ejection fraction (LVEF) \\> 50% confirmed by echocardiography, with no clinically significant pericardial effusion on echocardiography.\n* ⑥ No clinically significant pleural effusion.\n* ⑦ Baseline peripheral oxygen saturation (measured at the fingertip) \\> 92% while breathing room air.\n* 9.For women of childbearing potential: Non-lactating; negative result of highly sensitive serum or urine pregnancy test during screening. All women of childbearing potential must use medically accepted contraceptive methods (e.g., intrauterine device, oral contraceptives) throughout the treatment period and for 2 years after the first treatment. For males of childbearing potential: Sperm donation is prohibited during the same period.\n* 10.Ability to communicate effectively with investigators; willingness and ability to comply with the study protocol, complete all study-related procedures as required, and provide written informed consent (signed voluntarily by the patient or their legal guardian).\n\nExclusion Criteria:\n\n* 1.Isolated extramedullary leukemia or isolated extramedullary relapse.\n* 2.Central nervous system (CNS) involvement of leukemia at CNS2 stage.\n* 3.A history of other malignant tumors, except for the following: cured non-melanoma skin cancer, carcinoma in situ of the uterine cervix, localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ, or other malignant tumors with disease-free survival for more than 5 years.\n* 4.Positive test results for any of the following infectious diseases: HIV; HCV; HBsAg; positive HBcAb with concurrent positive HBV DNA copy number; TPPA.\n* 5.Administration of live or attenuated live vaccines within 4 weeks prior to enrollment.\n* 6.Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with tyrosine kinase inhibitor (TKI) therapy within 1 week prior to enrollment.\n* 7.Prior receipt of CD19-targeted therapy, CAR-T cell therapy, or other gene-edited T cell therapy.\n* 8.Grade ≥2 acute graft-versus-host disease (GVHD) (per Glucksberg criteria) requiring treatment, or extensive chronic GVHD (per Seattle criteria) within 4 weeks prior to enrollment; or patients judged by the investigator to potentially require anti-GVHD therapy during the study period.\n* 9.Comorbidities judged by the investigator to require systemic corticosteroid therapy or other immunosuppressive therapy during the study period; or receipt of allogeneic cellular therapy (e.g., donor lymphocyte infusion \\[DLI\\]) within 4 weeks prior to enrollment.\n* 10.Receipt of CNS-directed radiotherapy within 4 weeks prior to enrollment.\n* 11.Unresolved acute toxicities from prior therapy (excluding hematologic toxicities and alopecia) that have not recovered to Grade 1 or lower.\n* 12.Known life-threatening hypersensitivity or other intolerance to the study drug, or a history of severe atopy.\n* 13.Active autoimmune diseases (including but not limited to systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, etc.), excluding hypothyroidism that is controllable solely with hormone replacement therapy.\n* 14.Receipt of major surgery requiring general anesthesia within 4 weeks prior to enrollment; or failure to recover and achieve clinical stability from prior surgical treatment; or anticipated major surgery requiring general anesthesia during the study period.\n* 15.Use of other investigational drugs within 28 days prior to enrollment.\n* 16.A history of any unstable cardiovascular disease within 6 months prior to enrollment, including but not limited to unstable angina pectoris, myocardial infarction, heart failure (New York Heart Association \\[NYHA\\] Class ≥III), severe cardiac arrhythmias requiring pharmacologic treatment; or receipt of percutaneous transluminal coronary angioplasty, coronary stenting, or coronary artery bypass grafting within 6 months prior to enrollment.\n* 17.A history of central nervous system (CNS) disease or disorders (e.g., seizure disorders, cerebral vascular ischemia\u002Fhemorrhage, dementia, cerebellar disease) or any autoimmune disease involving the CNS.\n* 18.Uncontrolled active infection at screening (e.g., sepsis, bacteremia, fungemia, viremia).\n* 19.Any other condition judged by the investigator to make the patient unsuitable for participation in this clinical study.",{"count":556,"type":21},16,[165],"The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R\u002FR B-ALL). Participants who have signed the informed consent form will undergo screening against the inclusion and exclusion criteria. Eligible participants will receive study drug administration once weekly for a total of four doses, followed by a 1-year safety and efficacy follow-up observation period. After the completion of the study, long-term follow-up may be required for participants to monitor their health and survival status until 15 years post-treatment, or until the occurrence of patient death, loss to follow-up, or withdrawal of consent.",[560],"B-Cell Acute Lymphoblastic Leukemia",[560,562,563,564,565,566,567,568],"Relapsed Refractory Leukemia","CD19 Antigens","Chimeric Antigen Receptor T-Cells","circRNA","Nucleic Acids","Drug Safety","Clinical Study","2026-02-22",{"date":571,"type":35},"2026-02-24",{"date":573,"type":21},"2026-02-28",{"date":575,"type":21},"2041-12-31",{"name":41,"class":42},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":585,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":43},"100624891","phase-2-ibi343-combined-with-chemotherapy-as-neoadjuvant-therapy-in-borderline-resectable-pancreatic-cancer-100624891","NCT07415525","IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","A Phase II Clinical Study Evaluating the Safety and Efficacy of IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Subjects With Borderline Resectable Pancreatic Cancer","Inclusion Criteria:\n\n* (1)Sign a written Informed Consent Form (ICF), willing and able to comply with the visits and related procedures specified in the protocol.\n* (2)Histopathologically confirmed pancreatic adenocarcinoma.\n* (3)No evidence of distant metastasis as assessed by imaging (must include chest, abdomen, and pelvis). Bone scan or PET\u002FCT may be performed for confirmation if necessary.\n* (4)Confirmed borderline resectable pancreatic cancer as assessed by imaging (abdominal contrast-enhanced CT or contrast-enhanced MRI), with resectability determined according to the NCCN 2025.V2 guidelines for pancreatic cancer.\n* (5)No prior anti-tumor treatment for the studied disease, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.\n* (6)Age ≥18 years and ≤75 years, regardless of gender.\n* (7)Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n* (8)Expected survival ≥12 weeks.\n* (9)Adequate bone marrow and organ function.\n* (10)Female subjects of childbearing potential or male subjects with female partners of childbearing potential must use effective contraception throughout the treatment period and for 6 months after treatment.\n* (11)Confirmed \\*CLDN18.2 positivity by pathological tissue testing. \\*CLDN18.2 positivity is defined as Claudin18.2 immunohistochemical membrane staining intensity ≥1+ in ≥50% of tumor cells, accepting previous test results, results from the research center, or laboratory test results. Regarding the proportion of CLDN18.2 expression, the investigator and sponsor may dynamically adjust the criteria during the study based on newly generated data and data from other studies.\n\nExclusion Criteria:\n\n* (1)Currently participating in another interventional clinical study, excluding observational (non-interventional) clinical studies or being in the survival follow-up phase of an interventional study.\n* (2)The tumor is a locally recurrent lesion.\n* (3)Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) before the first dose of the investigational drug.\n* (4)Underwent biliary stent implantation or PTCD within 7 days before the first dose of the investigational drug.\n* (5)Received any live vaccine within 4 weeks before the first dose of the investigational drug or plans to receive one during the study period.\n* (6)Underwent major surgical procedures (craniotomy, thoracotomy, laparotomy, or other surgeries defined by the investigator, excluding needle biopsy) within 4 weeks before the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study period.\n* (7)History of gastrointestinal perforation and\u002For fistula within the past 6 months before the first dose of the investigational drug, which has not been resolved through surgical treatment.\n* (8)Pyloric obstruction affecting eating or gastric emptying that cannot be improved by jejunal feeding tube placement.\n* (9)Post-implantation of a stent in the digestive tract (referring to the muscular tube from the mouth to the anal canal, including the mouth, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, appendix, colon, rectum), and anal canal) or trachea. (Excluding stent placement included as part of radical surgery, such as duodenal stent placement in subjects with pancreatic head cancer.)\n* (10)Interstitial lung disease requiring steroid treatment, or a history of interstitial lung disease, non-infectious pneumonia, severely impaired lung function, or uncontrolled pulmonary conditions such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspicion of the above conditions during screening.\n* (11)Presence of uncontrolled diseases.\n* (12)History of other primary malignancies.\n* (13)Known history of immunodeficiency.\n* (14)History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* (15)Previously received antibody-drug conjugate therapy based on topoisomerase inhibitors.\n* (16)For subjects receiving medication, a history of allergy to the corresponding drug or formulation.\n* (17)For subjects receiving medication, contraindications to the corresponding drug.\n* (18)For subjects receiving medication, a history of permanent discontinuation of the corresponding drug due to adverse reactions.\n* (19)Pregnant or breastfeeding female subjects.\n* (20)Other conditions considered by the investigator as not suitable for participation in this study.",{"count":217,"type":21},[112],"This study is a Phase II trial evaluating the safety and efficacy of IBI343 in combination with chemotherapy as neoadjuvant therapy for subjects with borderline resectable pancreatic cancer (BRPC). The study enrolls treatment-naïve subjects with CLDN18.2-positive BRPC, confirmed by imaging and pathological diagnosis. Subjects will receive 4 cycles of neoadjuvant therapy. During or after neoadjuvant therapy, subjects who are unable to undergo radical surgical resection due to disease progression or other reasons will discontinue study treatment. After imaging assessment, subjects deemed eligible for radical resection by a multidisciplinary team (MDT) will undergo radical surgery 14-28 days after the last dose of neoadjuvant therapy . Following surgery, subjects will receive adjuvant therapy with the AG regimen or investigator-selected adjuvant chemotherapy. Adjuvant therapy will begin 21-56 days post-surgery, and the total duration of preoperative neoadjuvant and postoperative adjuvant therapy will be 6 months. Subjects will continue adjuvant therapy until the planned treatment duration is completed, or until disease recurrence, intolerable toxicity, withdrawal of informed consent, loss to follow-up, death, or other treatment discontinuation criteria are met (whichever occurs first). After discontinuation of study treatment, subjects will undergo safety follow-up and survival follow-up.",[588,589],"Pancreatic Cancer","Borderline Resectable Pancreatic Adenocarcinoma",[591,592,92],"borderline resectable pancreatic adenocarcinoma","Claudin 18.2 positive","2026-02-10",{"date":595,"type":35},"2026-02-17",{"date":597,"type":21},"2026-02-01",{"date":599,"type":21},"2030-12-31",{"name":41,"class":42},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":608,"targetDuration":4,"studyType":22,"phases":609,"briefSummary":610,"conditions":611,"keywords":612,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":124},"100611452","phase-2-hrs-4642-in-combination-with-nimotuzumab-and-chemotherapy-for-brpc-with-kras-g12d-mutation-100611452","NCT07240766","HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","Phase II Study of HRS-4642 in Combination With Nimotuzumab and Chemotherapy for Subjects With Borderline Resectable Pancreatic Cancer With KRAS G12D Mutation","Inclusion Criteria:\n\n* Aged between 18 and 75 years (inclusive).\n* Histopathologically confirmed pancreatic cancer (originating from the pancreatic ductal epithelium).\n* Radiologically confirmed borderline resectable pancreatic cancer (according to the latest NCCN guidelines definition), with no distant metastases.\n* Tumor tissue testing confirms KRAS G12D mutation.\n* No prior systemic anti-tumor therapy.\n* At least one evaluable lesion according to RECIST v1.1 criteria.\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.\n* Expected survival time ≥ 3 months.\n* Adequate organ function meeting the following requirements (no use of any blood components or colony-stimulating factors within 2 weeks prior to enrollment):\n\n  1. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL\n  2. Platelets ≥ 80 × 10⁹\u002FL\n  3. Hemoglobin ≥ 100 g\u002FL\n  4. Serum albumin ≥ 30 g\u002FL\n  5. Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN and ALP ≤ 2.5 × ULN\n  6. Creatinine clearance ≥ 50 mL\u002Fmin or Serum creatinine ≤ 1.5 × ULN (Calculation formula see section 13.3)\n  7. Electrocardiogram: QTcF ≤ 450 ms (male), QTcF ≤ 470 ms (female)\n  8. Cardiac ultrasound: LVEF (Left Ventricular Ejection Fraction) ≥ 50%\n* Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment, must be non-lactating, and must be willing to use adequate contraception during the trial and for 6 months after the end of treatment. For men, they must be surgically sterile or agree to use adequate contraception during the study and for 6 months after the end of treatment.\n* Voluntary participation in this study and signing of informed consent, good compliance, and agreement to cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Prior Treatment:\n\n  1. Major surgical procedure or significant traumatic injury within 4 weeks prior to enrollment, or palliative local therapy (including but not limited to palliative radiotherapy, interventional therapy) within 2 weeks prior to enrollment.\n  2. Treatment with any investigational drug from another clinical study within 4 weeks prior to enrollment, except for participation in an observational (non-interventional) clinical study or the follow-up phase of an interventional study.\n  3. Use of strong inhibitors or inducers of hepatic drug-metabolizing enzymes CYP3A4 or CYP2C8 within 14 days prior to enrollment.\n* 2\\. Acute or chronic pancreatitis requiring clinical intervention.\n* 3\\. History or presence of symptoms\u002Fsigns of gastrointestinal obstruction within 6 months prior to the start of study treatment. Subjects may be screened if they have undergone surgical procedure resulting in complete resolution of the obstruction.\n* 4\\. Third-space fluid accumulation (e.g., significant pleural effusion, ascites, etc.) that is unstable (unable to remain stable without intervention after drainage removal) within 2 weeks prior to enrollment. Subjects with only small amounts of fluid visible on imaging and without clinical symptoms may be enrolled.\n* 5\\. Severe infection within 4 weeks prior to enrollment, such as severe pneumonia, bacteremia, or infectious complications requiring hospitalization; Unexplained fever \\>38.5°C within 2 weeks prior to enrollment (subjects with fever judged by the investigator to be due to the tumor may be enrolled); Presence of signs\u002Fsymptoms of infection requiring intravenous antibiotic therapy within 2 weeks prior to enrollment (excluding prophylactic antibiotic use).\n* 6\\. Severe cardiovascular and cerebrovascular diseases:\n\n  1. Important arterial\u002Fvenous thrombotic events within 6 months prior to enrollment, such as cerebrovascular accident (including cerebral hemorrhage, cerebral infarction), deep vein thrombosis (excluding muscular venous thrombosis not requiring anticoagulation), and pulmonary embolism.\n  2. Poorly controlled cardiac symptoms or diseases, such as:\n\n     1. Myocardial infarction within 6 months.\n     2. Unstable angina.\n     3. Heart failure of NYHA class II or above.\n     4. Subjects with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.\n* 7\\. Patients with known or suspected interstitial lung disease, with the exception of interstitial changes visible only on imaging without clinical symptoms.\n* 8\\. History of definite neurological or psychiatric disorders, including epilepsy and dementia.\n* 9\\. Presence of non-healed wounds (severe, non-healing, or dehisced) or unhealed fractures.\n* 10\\. Adverse events from prior anti-cancer therapy have not recovered to NCI-CTCAE grade ≤1 (except for alopecia and parameters already specified in the inclusion criteria; except for AEs judged by the investigator as not affecting study drug administration).\n* 11\\. History of other malignant tumors within 5 years prior to enrollment, except for those with low risk of metastasis and death: adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, etc.\n* 12\\. Concurrent active Hepatitis B (if HBsAg positive, HBV DNA must be tested; HBV DNA \\\u003C2000 IU\u002FmL is required for enrollment and the subject must receive standard antiviral therapy during the study), Hepatitis C (HCV antibody positive and HCV-RNA above the lower limit of detection of the assay). Known history of acquired immunodeficiency syndrome or positive HIV test. Active syphilis infection. Active tuberculosis or history of active tuberculosis infection within 48 weeks prior to screening, regardless of treatment.\n* 13\\. Known allergy to any component of HRS-4642; history of allergy to Nimotuzumab, other monoclonal antibody\u002Ffusion protein drugs, albumin-bound paclitaxel, or gemcitabine.\n* 14\\. Any other condition that, in the judgment of the investigator, may affect the study results or lead to the premature termination of the study, such as alcoholism, drug abuse, other serious concomitant diseases (including psychiatric disorders) requiring treatment, severely abnormal laboratory test values, family or social factors, and other circumstances that may affect patient safety or reliability of data collection.",{"count":217,"type":21},[112],"This study is a Phase II clinical trial that plans to enroll 40 patients with borderline resectable pancreatic cancer harboring a KRAS G12D mutation, aiming to evaluate the efficacy of HRS-4642 in combination with Nimotuzumab and AG in borderline resectable pancreatic cancer. The study process includes a screening period (from the signing of the informed consent form until the first dose), a treatment period (from the first dose to the discontinuation of study treatment), and a follow-up period (safety follow-up and survival follow-up after the discontinuation of study treatment).",[589],[613,614,615],"pancreatic adenocarcinoma","borderline resectable","KRAS G12D mutation",{"date":617,"type":35},"2026-02-13",{"date":619,"type":21},"2026-02-15",{"date":621,"type":21},"2028-11-15",{"name":41,"class":42},{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":629,"eligibilityCriteria":630,"healthyVolunteers":631,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":632,"targetDuration":4,"studyType":22,"phases":634,"briefSummary":635,"conditions":636,"keywords":640,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":43},"100616587","efficacy-of-ai-assisted-colonoscopy-for-screening-colorectal-neoplasia-ai-coloscreen-100616587","NCT07307547","Efficacy of AI-Assisted Colonoscopy for Screening Colorectal Neoplasia (AI-COLOSCREEN)","A Multi-center, Randomized, Controlled Clinical Study on the Efficacy of Artificial Intelligence-Assisted Colonoscopy in Improving the Screening of Colorectal Cancer and Precancerous Lesions.","AI-COLOSCREEN","Inclusion Criteria:\n\n1. Age between 18 and 75 years, inclusive.\n2. Scheduled for a screening, diagnostic, or surveillance colonoscopy.\n3. Able to understand the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n1. Known contraindications to colonoscopy or biopsy.\n2. Personal history of colorectal cancer, inflammatory bowel disease (IBD), or previous colorectal surgery.\n3. Known or suspected colorectal polyposis syndrome (e.g., Familial Adenomatous Polyposis - FAP).\n4. Patients with active colorectal bleeding, bowel obstruction, or toxic megacolon.\n5. Women who are pregnant, planning to become pregnant, or are breastfeeding.\n6. Participation in another interventional clinical trial within the 30 days prior to enrollment.\n7. Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.",true,{"count":633,"type":21},3342,[24],"This study is a multi-center, randomized controlled trial designed to evaluate whether an artificial intelligence (AI) system can assist endoscopists to improve the detection rate of colorectal adenomas and cancers during colonoscopy compared to standard colonoscopy. Early screening and diagnosis are key to reducing the burden of colorectal cancer, but current colonoscopy has limitations, including the risk of missed lesions. This trial aims to determine if AI can enhance screening quality and diagnostic accuracy.",[637,638,639,221],"Colorectal Neoplasms","Colonic Polyp","Adenoma",[641,642,643,644,645],"Artificial Intelligence","Colonoscopy","Colorectal Cancer Screening","Adenoma Detection Rate","Deep Learning","2026-02-08",{"date":593,"type":35},{"date":649,"type":21},"2026-04",{"date":651,"type":21},"2028-12",{"name":41,"class":42},{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":4,"eligibilityCriteria":659,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":660,"targetDuration":4,"studyType":22,"phases":662,"briefSummary":663,"conditions":664,"keywords":667,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":680},"100510193","lish-trial-for-the-hepatic-flexure-and-proximal-transverse-colon-cancer-100510193","NCT05923255","LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer","Laparoscopic Ileocecal-Sparing Right Hemicolectomy for Cancer of the Hepatic Flexure and Proximal Transverse Colon -- A Prospective, Multicenter Randomized Control Clinical Trial","Inclusion Criteria:\n\n1. Age between 18-75 years old\n2. ASA classification ≤III\n3. Colon adenocarcinoma confirmed by endoscopy and pathological biopsy\n4. Enhanced abdominal CT indicating the primary lesion is located in the hepatic flexure of the colon or proximal transverse colon (proximal 1\u002F3 of the transverse colon)\n5. Preoperative clinical staging: TanyNanyM0\n6. Patients able to understand the study protocol, willing to participate in the research, and providing written informed consent\n\nExclusion Criteria:\n\n1. Preoperative examination indicates synchronous multiple primary colorectal cancers or other diseases requiring bowel segment resection\n2. Preoperative imaging or intraoperative exploration reveals: 1) tumor involving surrounding organs requiring combined organ resection; 2) presence of distant metastasis; 3) inability to perform R0 resection; 4) fused and fixed lymph nodes at the root of the ileocolic vessels\n3. Additional radical surgery following Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) procedures\n4. History of any other malignant tumor within the last 5 years or familial adenomatous polyposis, except for cured in situ cervical cancer, basal cell carcinoma, papillary thyroid carcinoma, or skin squamous cell carcinoma\n5. Presence of bowel obstruction, bowel perforation, or intestinal bleeding requiring emergency surgery\n6. Patients unsuitable for or unable to tolerate laparoscopic surgery\n7. Pregnant or lactating women\n8. Patients with a history of psychiatric disorders\n9. Patients who have received neoadjuvant therapy prior to surgery\n10. Patients deemed unsuitable for the study by MDT discussion\n11. Patients unable to understand the study's conditions and objectives, and refusing to sign informed consent.",{"count":661,"type":21},568,[24],"The goal of this clinical trial is to compare the long-term outcomes of Laparoscopic Ileocecal-Sparing Right Hemicolectomy(LISH) compared to traditional laparoscopic right hemicolectomy(TRH) in the treatment of hepatic flexure colon cancer and proximal transverse colon cancer.",[665,666],"Hepatic Flexure Colon Cancer","Proximal Transverse Colon Cancer",[668,669,670,671],"hepatic flexure colon cancer","proximal transverse colon cancer","ileocecus-sparing","laparoscopic right hemicolectomy","2026-01-25",{"date":674,"type":35},"2026-01-27",{"date":676,"type":35},"2023-05-14",{"date":678,"type":21},"2031-05-14",{"name":41,"class":42},29,""]